Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
In this article:
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.